Leading the Way in Oncology and Hematology

We devote an exceptional breadth and depth of clinical trial experience and scientific expertise to our work advancing research in oncology and hematology. From our work on the first-ever development program for a checkpoint inhibitor to designing today’s most innovative cancer clinical trials, our experts dedicated to oncology and hematology – more than 3,500 of us – have a history of embracing bold visions and bringing passion, focus and skill to the business of realizing them.

 

 

Expert Partnership

 

 

At Syneos Health, more than 3,500 CRAs, project managers, medical directors and executive leadership are focused solely on oncology and hematology. They bring a wealth of experience and strong site and investigator relationships to ensure the successful delivery of your clinical development plans.

 

 

Therapeutic Depth and Expertise

 

 

変化を受け入れ、イノベーションを主導する

 

当チームは新規オンコロジー薬剤、ファーストインペイシェント試験、複雑な治験実施計画、および最先端科学に関する豊富な経験を有します。臨床イノベーションの最前線でがん治験を実施し、患者さんのアウトカムの向上を目指して、つねに業界をリードしています。

  • がん免疫療法に関する多種多様な実績
    • Monoclonal antibodies, checkpoint inhibitors, vaccines, targeted therapies, gene therapies and adoptive cell transfer technologies
  • 医薬品開発および治療法への斬新なアプローチ
    • Precision medicine, investigator-led and cooperative group trials, basket studies and umbrella trials, such as the Leukemia and Lymphoma Society's  "Beat AML" Master Trial

Drawing on our depth and breadth of experience, we identify important issues that can otherwise be overlooked during protocol design and study execution such as access to patients for rare disease studies, the challenges of biologic and targeted therapy development, competing studies, trial design complexity/technicality and novel mechanisms of action.

 

 

Bridging from Clinical Development to Commercialization

 

Our oncology and hematology expertise runs deep and also wide – extending beyond clinical development to commercialization of oncology therapeutics:

 

At Syneos Health, Shortening the Distance from Lab to Life® means that insights across the clinical-commercial continuum are used to help define the most effective, cost-efficient pathway for accelerating oncology drug development and their availability to patients.

詳しくは: 
  • オンコロジー
  • 早期臨床試験
05.27.19
  • 被験者登録
  • オンコロジー
  • 治験
05.29.19
  • オンコロジー及び血液学
  • オンコロジー
  • Non-Malignant Hematology
05.31.19
Powered by Translations.com GlobalLink OneLink Software